Experimental combo for tough lung cancer hits early snag

NCT ID NCT04081688

Terminated Disease control Sponsor: Rutgers, The State University of New Jersey Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a combination of two immunotherapy drugs (atezolizumab and varlilumab) plus targeted radiation in 16 people with advanced non-small cell lung cancer that had stopped responding to standard treatment. The goal was to see if the triple therapy was safe and could slow the cancer's growth. The study was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atezolizumab, varlilumab, and radiation therapy
What this could lead to: If it works, this combination could help control advanced lung cancer that has stopped responding to standard immunotherapy.
What could go wrong: This was a very early, small trial (16 people) that was terminated, so we don't know if the combination is safe or effective. Side effects from the drugs and radiation can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

REFRACTORY LUNG NON-SMALL CELL CARCINOMA STAGE IV LUNG CANCER AJCC V8

Contacts and locations

Locations

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.